Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT05835310

PHASE3

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, and Safety of Anifrolumab in Children with Moderate to Severe Active Systemic Lupus Erythematosus (SLE)

Official title: A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Moderate to Severe Active Systemic Lupus Erythematosus While on Background Standard of Care Therapy

Key Details

Gender

All

Age Range

5 Years - 17 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2024-03-14

Completion Date

2030-01-09

Last Updated

2026-04-06

Healthy Volunteers

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL

Anifrolumab

Participants will receive anifrolumab via IV infusion.

DRUG

Placebo

Participants will receive matching placebo via IV infusion

Inclusion Criteria: * Participant's parent/caregiver/legally authorized representative and participant (if required per local country regulation) capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. Informed assent is to be provided by the participant per local country regulation. * Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) criteria for at least 3 months prior to signing the ICF. * Participant should meet all of following tuberculosis (TB) criteria: A. No signs or symptoms of active TB B. No medical history or past physical examinations suggestive of active TB C. No recent contact with a person with active TB or if there has been such contact, referral to a TB specialist for evaluation and initiation of treatment for latent TB, if warranted, prior to the first administration of study intervention in accordance with local SoC D. No history of latent TB without documented completion of treatment prior to initial screening visit * Female participants of childbearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test at randomization. * Female participants of childbearing and male participants must adhere to the contraception methods. Exclusion Criteria: * Known diagnosis of an IFN-mediated autoinflammatory interferonopathy. * History of, or current diagnosis of, clinically significant non-SLE-related vasculitides. * In participants aged 11 years and above: history or evidence of suicidal ideation. * History of any non-SLE disease that has required treatment with oral or parenteral corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to signing the ICF. * Any positive result on screening for human immunodeficiency virus. * Active hepatitis B surface antigen OR hepatitis B core antibody (HBcAb), hepatitis C virus (HCV) antibody and detectable HCV ribonucleic acid (RNA) or any active or recent case of Herpes Zoster infection. * Any clinical cytomegalovirus or Epstein-Barr virus infection that has not completely resolved within 12 weeks prior to signing the ICF. * History of severe COVID-19 infection requiring hospitalization, intensive care unit care, or assisted ventilation or any prior COVID-19 infection with unresolved sequelae. Any mild/asymptomatic COVID-19 infection (laboratory confirmed or suspected based on clinical symptoms). * Prior use of anifrolumab. * Prior treatment with directly acting cytotoxic B-cell depleting therapeutics (eg, rituximab) \< 26 weeks prior to ICF signature. * Blood transfusion or receipt of blood products except albumin within 4 weeks prior to signing the ICF.

Locations (97)

Research Site

Phoenix, Arizona, United States

Research Site

Los Angeles, California, United States

Research Site

Washington D.C., District of Columbia, United States

Research Site

Chicago, Illinois, United States

Research Site

Chicago, Illinois, United States

Research Site

New Orleans, Louisiana, United States

Research Site

Bethesda, Maryland, United States

Research Site

Saint Paul, Minnesota, United States

Research Site

New Hyde Park, New York, United States

Research Site

New York, New York, United States

Research Site

The Bronx, New York, United States

Research Site

Valhalla, New York, United States

Research Site

Durham, North Carolina, United States

Research Site

Cincinnati, Ohio, United States

Research Site

Cleveland, Ohio, United States

Research Site

Columbus, Ohio, United States

Research Site

Portland, Oregon, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

Greenville, South Carolina, United States

Research Site

El Paso, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Salt Lake City, Utah, United States

Research Site

Buenos Aires, Argentina

Research Site

Córdoba, Argentina

Research Site

Rosario, Argentina

Research Site

San Miguel de Tucumán, Argentina

Research Site

Porto Alegre, Brazil

Research Site

Ribeirão Preto, Brazil

Research Site

São Paulo, Brazil

Research Site

São Paulo, Brazil

Research Site

Calgary, British Columbia, Canada

Research Site

Vancouver, British Columbia, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Changchun, China

Research Site

Changsha, China

Research Site

Nanjing, China

Research Site

Shanghai, China

Research Site

Suzhou, China

Research Site

Wenzhou, China

Research Site

Zhengzhou, China

Research Site

Barranquilla, Colombia

Research Site

Medellín, Colombia

Research Site

Bordeaux, France

Research Site

Bron, France

Research Site

Le Kremlin-Bicêtre, France

Research Site

Lille, France

Research Site

Toulouse, France

Research Site

Berlin, Germany

Research Site

Freiburg im Breisgau, Germany

Research Site

Sankt Augustin, Germany

Research Site

Genova, Italy

Research Site

Milan, Italy

Research Site

Milan, Italy

Research Site

Padova, Italy

Research Site

Roma, Italy

Research Site

Bunkyō City, Japan

Research Site

Bunkyō City, Japan

Research Site

Chiba, Japan

Research Site

Fuchu-shi, Japan

Research Site

Kawasaki-shi, Japan

Research Site

Kobe, Japan

Research Site

Obu-shi, Japan

Research Site

Shinjuku-ku, Japan

Research Site

Yokohama, Japan

Research Site

Yokohama, Japan

Research Site

Atizapán de Zaragoza, Mexico

Research Site

Guadalajara, Mexico

Research Site

Mérida, Mexico

Research Site

México, Mexico

Research Site

Monterrey, Mexico

Research Site

Lodź, Poland

Research Site

Warsaw, Poland

Research Site

Wroclaw, Poland

Research Site

Lisbon, Portugal

Research Site

Lisbon, Portugal

Research Site

Porto, Portugal

Research Site

Cape Town, South Africa

Research Site

Esplugues de Llobregat, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Málaga, Spain

Research Site

Santiago de Compostela, Spain

Research Site

Valencia, Spain

Research Site

Ankara, Turkey (Türkiye)

Research Site

Istanbul, Turkey (Türkiye)

Research Site

Kayseri, Turkey (Türkiye)

Research Site

Umraniye, Turkey (Türkiye)

Research Site

Birmingham, United Kingdom

Research Site

Bristol, United Kingdom

Research Site

Liverpool, United Kingdom

Research Site

London, United Kingdom

Research Site

London, United Kingdom

Research Site

Manchester, United Kingdom

Research Site

Southampton, United Kingdom

Clinical Research Directory

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (97)